Also listed on Capella Bioscience Ltd., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Feb 13, 2039 · High confidence
20-year base term ends Jan 24, 2038
Filed Jul 24, 2019 as application 16/480,367 · Granted Nov 28, 2023
Base term plus 385 days of patent term adjustment (USPTO delay)
Today
2018
2039
Clock starts
Jan 24, 2018
Jan 24, 2018
Term ends
Feb 13, 2039
Feb 13, 2039
Granted
Nov 28, 2023
Nov 28, 2023
base term
patent term adjustment
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
385
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 385 days past its 20-year base term on prosecution delay. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jan 24, 2018, when application PCT/GB2018/050203, the earliest non-provisional in its chain, was filed (this one was filed Jul 24, 2019) | Jan 24, 2038 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +385 days, USPTO patent term adjustment record | Feb 13, 2039 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Feb 13, 2039 | High confidence |
This family
| US 11,827,673 | this patent Feb 2039 | Feb 2039 |
| Application 18/480,379 | Abandoned not computed | not computed |
2 of 3 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 20, 2020 Reel 54703, frame 568 | Holmes, Steve | Capella Bioscience Ltd. | Assignment of Assignor's Interest |
| Oct 4, 2021 Reel 57710, frame 82 | Apcintex Limited; Janpix Limited; Capella Bioscience Ltd.; Lockbody Therapeutics Ltd.; Ultrahuman Two Limited; Ultrahuman Four Limited; Morphogen-IX Limited; Orexia Therapeutics Limited; Cardiokine Biopharma LLC; Palladio Biosciences, Inc.; Pearlriver Bio GmbH; Z Factor Limited | Cocoon S.A. LLC | Security Interest |
| Sep 28, 2023 Reel 65056, frame 399 | Capella Bioscience Ltd. | Centessa Pharmaceuticals (UK) Limited | Assignment of Assignor's Interest |
| Sep 28, 2023 Reel 65056, frame 470 | Holmes, Steve | Capella Bioscience Ltd. | Assignment of Assignor's Interest |
| Dec 31, 2024 Reel 69708, frame 39 | Centessa Pharmaceuticals (UK) Limited | Oxford Finance LLC | Security Interest |
| Jun 12, 2026 Reel 75737, frame 1 | Cocoon S.A. LLC | Apcintex Limited; Janpix Limited; Capella Bioscience Ltd.; Lockbody Therapeutics Ltd.; Ultrahuman Two Limited; Ultrahuman Four Limited; Morphogen-IX Limited; Orexia Therapeutics Limited; Cardiokine Biopharma LLC; Centessa Biosciences, Inc.; Pearlriver Bio GmbH; Z Factor Limited | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Apcintex Limited | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Janpix Limited | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Capella Bioscience Ltd. | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Lockbody Therapeutics Ltd. | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Ultrahuman Two Limited | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Ultrahuman Four Limited | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Morphogen-IX Limited | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Orexia Therapeutics Limited | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Cardiokine Biopharma LLC | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Centessa Biosciences, Inc. | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Pearlriver Bio GmbH | Release of Security Interest |
| Jun 12, 2026 reel/frame not recorded | Cocoon S.A. LLC | Z Factor Limited | Release of Security Interest |
| Jun 24, 2026 Reel 75069, frame 879 | Oxford Finance LLC | Centessa Pharmaceuticals (UK) Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Feb 2039
Term ends Feb 13, 2039. Maintenance fees still fall due before then
Note
The 385 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.